Kinnate Biopharma (KNTE) Social Stream
Kinnate Biopharma Inc (KNTE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Kinnate Biopharma Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
KNTE's average price target has moved down $4.4 over the prior 152 days.
KNTE reports an average of 150.74% for its upside potential over the past 49 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
KNTE Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 120 days, KNTE's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for KNTE as an investment opportunity.
- Kinnate Biopharma Inc's upside potential (average analyst target price relative to current price) is greater than 464.59% of all US stocks.
- To contextualize these metrics, consider that out of stocks in the small market cap category, Kinnate Biopharma Inc's average analyst price target is greater than 420.6% of them.
- In the context of stocks in the small market cap category, Kinnate Biopharma Inc's number of analysts covering the stock is higher than 389.5% of them.
- In the context of Pharmaceutical Products stocks, Kinnate Biopharma Inc's variance in analysts' estimates is lower than -79.72% of them.
Make investment decisions regarding KNTE using the data that counts. Try POWR Ratings for free.